Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Indevus finalizes supply agreement with Schering AG
The disorder, also known as male hypogonadism, is the inability of the testicles to produce testosterone, sperm or both. In July 2005, Indevus licensed the exclusive US rights
The disorder, also known as male hypogonadism, is the inability of the testicles to produce testosterone, sperm or both. In July 2005, Indevus licensed the exclusive US rights
The agreement will give Barr a strong position in the biopharmaceutical market and will give the company access to new drug delivery technologies. The agreement will also provide
The siRNA therapeutic is developed to target cancer. The therapeutic candidate was well tolerated at doses significantly higher than those shown to be successful in previous studies. Calando
“Treating acute bipolar disorder with a single medication may help patients adhere to their medication regimen,” said John Patterson, executive director of development at AstraZeneca. The FDA approval
The trial is expected to be the largest ever to be conducted in small cell lung cancer and will assess the potential clinical benefit of Alimta in combination
The group has specifically raised issue with the drug’s side effects. The National Autism Association issued a warning letter in 2004 to Janssen, a subsidiary of Johnson &
Conventional vaccines under development for avian flu typically have required two or more doses in humans. A single-dose vaccine regimen could prove beneficial during a pandemic, both in
The study was designed to assess the safety of a single treatment with efficacy parameters recorded as secondary variables. AM-Pharma is developing a unique therapy against sepsis, based
The move comes two weeks after the retailer rolled out the low-cost program in Florida, in what would appear a bid to draw in more shoppers into its
Included in the 2005 results was a charge of $124 million before a tax benefit of $6 million, or 8 cents per share, related to an R&D payment.